Antiangiogenic Therapy for Ischemic Retinopathies

Overview

Journal Cold Spring Harb Perspect Med

Specialty General Medicine

Date 2012 Jun 8

PMID 22675660

Citations 38

Authors

Motasem Al-Latayfeh

Paolo S Silva

Jennifer K Sun

Lloyd Paul Aiello

Affiliations

Soon will be listed here.

Abstract

Neovascularization is a common pathological process in various retinal vascular disorders including diabetic retinopathy (DR), age-related macular degeneration (AMD) and retinal vein occlusion (RVO). The development of neovascular vessels may lead to complications such as vitreous hemorrhage, fibrovascular tissue formation, and traction retinal detachments. Ultimately, irreversible vision loss may result. Various proangiogenic factors are involved in these complex processes. Different antiangiogenic drugs have been formulated in an attempt treat these vascular disorders. One factor that plays a major role in the development of retinal neovascularization is vascular endothelial growth factor (VEGF). Anti-VEGF agents are currently FDA approved for the treatment of AMD and RVO. They are also extensively used as an off-label treatment for diabetic macular edema (DME), proliferative DR, and neovascular glaucoma. However, at this time, the long-term safety of chronic VEGF inhibition has not been extensively evaluated. A large and rapidly expanding body of research on angiogenesis is being conducted at multiple centers across the globe to determine the exact contributions and interactions among a variety of angiogenic factors in an effort to determine the therapeutic potential of antiangiogenic agent in the treatment of a variety of retinal diseases.

Citing Articles

Interleukin-1 receptor-dependent and -independent caspase-1 activity in retinal cells mediated by receptor interacting protein 2.

Coughlin B, Christian B, Trombley B, Mohr S Front Cell Dev Biol. 2024; 12:1467799.

PMID: 39483336 PMC: 11525982. DOI: 10.3389/fcell.2024.1467799.

Impact of the Nationwide Avastin Ban at a Tertiary Eye Care Hospital in Pakistan.

Shaheen F, Farooq H, Amjad M Cureus. 2024; 16(7):e65199.

PMID: 39176343 PMC: 11341108. DOI: 10.7759/cureus.65199.

G protein subunit alpha i2's pivotal role in angiogenesis.

Bai C, Lu L, Zhang J, Zhou C, Ni Y, Li K Theranostics. 2024; 14(5):2190-2209.

PMID: 38505600 PMC: 10945342. DOI: 10.7150/thno.92909.

Assessment of Inner Blood-Retinal Barrier: Animal Models and Methods.

Bora K, Kushwah N, Maurya M, Pavlovich M, Wang Z, Chen J Cells. 2023; 12(20).

PMID: 37887287 PMC: 10605292. DOI: 10.3390/cells12202443.

PLAC8-Mediated Activation of NOX4 Signalling Restores Angiogenic Function of Endothelial Colony-Forming Cells in Experimental Hypoxia.

Pun S, ONeill K, Edgar K, Gill E, Moez A, Naderi-Meshkin H Cells. 2023; 12(18).

PMID: 37759443 PMC: 10526321. DOI: 10.3390/cells12182220.

References

Suri C, Jones P, Patan S, Bartunkova S, Maisonpierre P, Davis S . Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996; 87(7):1171-80. DOI: 10.1016/s0092-8674(00)81813-9. View

Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

Ozaki H, Yu A, Della N, Ozaki K, Luna J, Yamada H . Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci. 1999; 40(1):182-9. View

Shen L, Child A, Weber G, Folkman J, Aiello L . Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol. 2008; 126(6):793-9. DOI: 10.1001/archopht.126.6.793. View

Boyer D, Heier J, Brown D, Francom S, Ianchulev T, Rubio R . A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009; 116(9):1731-9. DOI: 10.1016/j.ophtha.2009.05.024. View

Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F . Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008; 115(9):1571-80, 1580.e1-3. DOI: 10.1016/j.ophtha.2008.02.026. View

Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R . Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology. 2009; 116(10):1943-8. DOI: 10.1016/j.ophtha.2009.07.001. View

Peer J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E . Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology. 1998; 105(3):412-6. DOI: 10.1016/S0161-6420(98)93020-2. View

Brown D, Campochiaro P, Singh R, Li Z, Gray S, Saroj N . Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117(6):1124-1133.e1. DOI: 10.1016/j.ophtha.2010.02.022. View

10.

Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, Clermont A, Leitges M, Marette A . Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med. 2009; 15(11):1298-306. PMC: 3290906. DOI: 10.1038/nm.2052. View

11.

Gregori N, Gaitan J, Rosenfeld P, Puliafito C, Feuer W, Flynn Jr H . Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. Retina. 2009; 28(9):1325-37. DOI: 10.1097/IAE.0b013e318188501f. View

12.

Xia P, Aiello L, Ishii H, Jiang Z, Park D, Robinson G . Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest. 1996; 98(9):2018-26. PMC: 507645. DOI: 10.1172/JCI119006. View

13.

Bashshur Z, Haddad Z, Schakal A, Jaafar R, Saad A, Noureddin B . Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol. 2009; 148(1):59-65.e1. DOI: 10.1016/j.ajo.2009.02.006. View

14.

Phipps J, Clermont A, Sinha S, Chilcote T, Bursell S, Feener E . Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability. Hypertension. 2009; 53(2):175-81. PMC: 4978181. DOI: 10.1161/HYPERTENSIONAHA.108.117663. View

15.

Klein R, Peto T, Bird A, Vannewkirk M . The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004; 137(3):486-95. DOI: 10.1016/j.ajo.2003.11.069. View

16.

Votruba M, Gregor Z . Neovascular age-related macular degeneration: present and future treatment options. Eye (Lond). 2001; 15(Pt 3):424-9. DOI: 10.1038/eye.2001.147. View

17.

Erdol H, Turk A, Akyol N, Imamoglu H . The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy. Retina. 2010; 30(4):570-7. DOI: 10.1097/IAE.0b013e3181bf5ff0. View

18.

Nguyen Q, Shah S, Browning D, Hudson H, Sonkin P, Hariprasad S . A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology. 2009; 116(11):2141-8.e1. DOI: 10.1016/j.ophtha.2009.04.030. View

19.

Ferrara N, Henzel W . Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989; 161(2):851-8. DOI: 10.1016/0006-291x(89)92678-8. View

20.

Jorge R, Costa R, Calucci D, Cintra L, Scott I . Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina. 2006; 26(9):1006-13. DOI: 10.1097/01.iae.0000246884.76018.63. View